VWF and hypertensive disorder: Jensen et al. [28] found that average level of vonWillebrand factor was reduced by 15% in patients with hypertension afternattokinase supplementation, whereas consistent change was not found for subjectsconsuming placebo after 8 weeks (p < 0.09).